Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fecal Microbiota Transplantation in aGvHD After ASCT
Sponsor: Medical University of Graz
Summary
Acute graft-versus-host-disease (aGvHD) is a typical complication after allogeneic hematopoetic stem cell transplantation (ASCT). About 30-60% of patients after ASCT are affected by aGvHD, which constitutes a relevant burden of morbidity and mortality in these patients. Fecal microbiota transplantation (FMT) is a therapeutic concept to treat intestinal dysbiosis of various origin by infusion of the stool microbiota of a healthy donor into the gastrointestinal tract (GI) of a patient. FMT can be performed endoscopically by colonoscopic deployment of the donor microbiota into the patient´s caecum and terminal ileum. Patients with gastrointestinal aGvHD (GI-aGvHD) are known to comprise a significant dysbiotic colonic microbiota that can be attenuated by FMT.
Official title: Fecal Microbiota Transplantation in Patients With Acute Gastrointestinal Graft-versus-host-disease After Allogeneic Stem Cell Transplantation
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2017-03-01
Completion Date
2026-12-31
Last Updated
2025-12-02
Healthy Volunteers
No
Conditions
Interventions
Fecal microbiota transplantation
200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
Locations (1)
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz
Graz, Styria, Austria